More than a possibility, if we see what happened to ACAD. Things have changed over the past 25 odd years, since Amgen was launched. The markets have grown, better and faster connected to world markets. The FDA policies have gone a sea change. There is a lot of emphasis on early detection and treatment of symptoms. Orphan status is a lip smacking incentive for any biotech, especially startups. If LymPro, NuroPro and MANF continue to show promise and repeatable results, $50-100 pps is not a far fetched fantasy. It could happen in a year's time. At the OneMed Conf in Jan 2012, I could see the excitement in Dr. Rubinfeld's brief 3 minute talk, when he said we want to take MANF to the market asap. Many of the posters/investors here have no idea what AMBS is doing. They are here just for a quick 10% profit. It will benefit them to google and listen to all AMBS presentations since Jan 2012.
Actually, Let us forget about $50+. Let us suppose the pps is $1 and gains 5 cents, to become $1.05. That is a 5 percent gain. If you buy now when the pps is 5 cents, every 5 cent increment is 100% gain. I honestly do not see any real risk in investing in AMBS. If the pps sinks, just buy more. That is what we have been doing since January 2013. I have bought at 0.17, 0.16, 0.09, 0.06, 0.05, 0.04, 0.03, with an average of 0.05. If EVERYTHING that AMBS has fails, we all know that LymPro alone will still take AMBS to $0.50-1.00. In any case, those who think that AMBS is a risk, well, everything in the stock market is a risk, isn't it?
I ask, tell us one stock that does not have any risk? Believe it or not, AMBS is not the worst answer.
